Supported by grants from the Japan Society for the Promotion of Science (JSPS; Grant-in-Aid for Scientific Research, no. 21592256; Tokyo, Japan), the Japan National Society for the Prevention of Blindness (Tokyo, Japan), and the Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project for Developing Innovation Systems, from the Ministry of Education, Culture, Sports, Science and Technology (MEXT; Tokyo, Japan).
Disclosure: Y. Muraoka, Bayer (F), Novartis Pharma K.K. (F), Senju (F), (F); A. Uji, Bayer (F), Novartis Pharma K.K. (F), Senju (F), Nidek (F), Canon (F); M. Ishikura, None; Y. Ida, None; S. Ooto, Alcon Pharma (F), Bayer (F), Santen (F), Senju (F), Japan Focus (F), Nidek (F), Pfizer (F); A. Tsujikawa, Pfizer (F), Novartis Pharma K.K. (F), Bayer (F), Alcon (F), Santen (F), Senju (F), Nidek (F), AMO Japan (F), Kowa-Pharmaceutical (F), Chugai Pharmaceutical (F), Sanwa Kagaku (F), Kyoto Drug Discovery & Development (F), Hoya (F), Otsuka Pharmaceutical (F), Daiichi-Sankyo Company (F), Wakamoto (F), Johnson and Johnson (F), and Janssen Pharmaceutical K.K. (F), Canon (F), Alcon Pharma (F), JMIA (F), Tomey Corporation (F), JFC Sales Plan (F), Atsuzawa Prosthese Osaka (F)